Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ASHISH KAMAT and PADMANEE SHARMA.
Connection Strength

0.993
  1. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
    View in: PubMed
    Score: 0.246
  2. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.188
  3. Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 09 28; 5(1):80.
    View in: PubMed
    Score: 0.152
  4. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68.
    View in: PubMed
    Score: 0.151
  5. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
    View in: PubMed
    Score: 0.091
  6. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
    View in: PubMed
    Score: 0.084
  7. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30; 105(39):14987-92.
    View in: PubMed
    Score: 0.081
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.